Fig. 1: Structure of Angiotensin converting enzyme II (ACE2) expressed on the surface of cells in human airways epithelia.


Due to the unprecedented disruption of COVID-19 our preclinical R&D resumes in Q3/2020. The structured de-risking of the HAIROID project will conclude, with CLINICAL PHASE 1, earliest in Q4/ 2023. We expect a finalized EMA approval earliest in Q4 2025.